患者由来異種移植片（PDX）モデルの世界市場レポート 2025年

患者由来異種移植片（PDX）モデルの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR16.0％で8億5,000万米ドルに成長します。予測期間の成長は、個別化医療への需要、ヒト化PDXモデルの需要増加、がん罹患率の増加、精密腫瘍学への注目、がん研究のための研究開発投資の増加に起因すると考えられます。予測期間における主な動向としては、技術開発、ヒト化PDXモデルの需要増加、共同研究イニシアティブ、がん研究投資の増加、免疫腫瘍学への注目の高まりなどが挙げられます。

個別化医療の需要は、患者由来異種移植（PDX）モデル市場の成長を促進すると予想されます。個別化医療は、遺伝、環境、ライフスタイルなど、個々の患者の特性に合わせた治療を行うものです。このような需要は、個人の遺伝子プロファイルに基づく治療を促進し、より効果的で的を絞ったヘルスケアにつながるゲノム研究の進歩により高まっています。PDXモデルは、個々の患者の腫瘍を検査して治療反応を予測し、治療法を調整することで、個別化医療をサポートします。例えば、2024年2月、個別化医療連合（PMC）は、FDAが2023年に希少疾患に対する16の新しい個別化治療を承認したと報告しました。このように、個別化医療の需要はPDXモデル市場の成長を促進しています。

PDXモデル市場の主要企業は、リアルタイムの腫瘍増殖モニタリングのためのin vivo生物発光イメージング機能を備えた革新的なモデルを開発しています。このイメージング技術は、腫瘍の転移や治療反応を非侵襲的にモニタリングできるようにすることでPDXモデルを強化し、前臨床医薬品開発研究の有効性を向上させる。例えば、2024年3月、インドのCRO（医薬品開発業務受託機関）であるInVitro Research Solutions Private Limitedは、PDXとin vivoバイオルミネッセンスイメージングを用いたNSG-SGM3マウスのヒト膠芽腫の革新的な同所性モデルを発表しました。このモデルは、侵襲性の高い脳腫瘍である膠芽腫の個別化治療を可能にすることを目的としており、膠芽腫の生物学を理解し、転帰を改善するための新たな標的療法や免疫療法を評価するために不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界患者由来異種移植片（PDX）モデルPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の患者由来異種移植片（PDX）モデル市場：成長率分析
• 世界の患者由来異種移植片（PDX）モデル市場の実績：規模と成長, 2019-2024
• 世界の患者由来異種移植片（PDX）モデル市場の予測：規模と成長, 2024-2029, 2034F
• 世界患者由来異種移植片（PDX）モデル総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の患者由来異種移植片（PDX）モデル市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• マウスモデル
• ラットモデル
• 世界の患者由来異種移植片（PDX）モデル市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 異所性移植
• 直交異方性インプラント
• 世界の患者由来異種移植片（PDX）モデル市場腫瘍の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消化管腫瘍モデル
• 肺腫瘍モデル
• 血液腫瘍モデル
• 婦人科腫瘍モデル
• 呼吸器腫瘍モデル
• 泌尿器腫瘍モデル
• その他の腫瘍モデル
• 世界の患者由来異種移植片（PDX）モデル市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前臨床医薬品開発
• 精密医療
• 共同臨床試験
• 基礎がん調査
• 世界の患者由来異種移植片（PDX）モデル市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 学術調査機関
• 契約調査機関
• 製薬およびバイオテクノロジー企業
• その他のエンドユーザー
• 世界の患者由来異種移植片（PDX）モデル市場マウスモデルのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫不全マウスモデル（ヌードマウス、SCIDマウス）
• ヒト化マウスモデル
• 遺伝子組み換えマウスモデル
• 世界の患者由来異種移植片（PDX）モデル市場ラットモデルのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫不全ラットモデル
• ヒト化ラットモデル
• 遺伝子組み換えラットモデル

第7章 地域別・国別分析

• 世界の患者由来異種移植片（PDX）モデル市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の患者由来異種移植片（PDX）モデル市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 患者由来異種移植片（PDX）モデル市場：競合情勢
• 患者由来異種移植片（PDX）モデル市場：企業プロファイル
  • Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • The Jackson Laboratory Overview, Products and Services, Strategy and Financial Analysis
  • Inotiv Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Biocytogen Pharmaceuticals Co. Ltd.
• Taconic Biosciences Inc.
• BioDuro-Sundia Inc.
• Horizon Discovery Ltd.
• Crown Bioscience Inc.
• Champions Oncology Inc.
• Oncodesign Services S.A.
• Genesis Biotechnology Group LLC.
• Creative Animodel
• Abnova Corp.
• Certis Oncology Solutions Inc.
• Xentech
• Aragen Bioscience Inc.
• EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH.
• Urosphere

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 患者由来異種移植片（PDX）モデル市場2029：新たな機会を提供する国
• 患者由来異種移植片（PDX）モデル市場2029：新たな機会を提供するセグメント
• 患者由来異種移植片（PDX）モデル市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Patient-derived xenograft (PDX) models involve the transplantation of human tumor tissue into immunodeficient animal hosts. These models replicate the complexity of human tumors more accurately than traditional cell line models. PDX models are essential for studying tumor biology and testing potential cancer therapies before they reach clinical trials.

The primary types in the patient-derived xenograft (PDX) models market are mice models and rat models. Mice models are laboratory mice that have been genetically modified or bred to study specific biological processes, diseases, or treatment responses, supporting biomedical and pharmaceutical research. The various techniques include heterotopic implantation and orthotopic implantation, and encompass several types of tumors such as gastrointestinal tumor models, lung tumor models, hematological tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, and others. PDX models are used in preclinical drug development, precision medicine, co-clinical trials, and basic cancer research by academic institutions, research organizations, pharmaceutical companies, biotechnology firms, and other entities.

The patient derived xenograft (PDX) models market research report is one of a series of new reports from The Business Research Company that provides patient derived xenograft (PDX) models market statistics, including the patient derived xenograft (PDX) models industry global market size, regional shares, competitors with patient derived xenograft (PDX) models market share, detailed patient derived xenograft (PDX) models market segments, market trends, and opportunities, and any further data you may need to thrive in the patient derived xenograft (PDX) models industry. These patient derived xenograft (PDX) models market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The patient derived xenograft (PDX) models market size has grown rapidly in recent years. It will grow from $0.4 billion in 2024 to $0.47 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to research & development investments, regulatory support, partnerships and collaborations, increasing number of contract research organizations (CROs), and rising number of cancer cases.

The patient derived xenograft (PDX) models market size is expected to see rapid growth in the next few years. It will grow to $0.85 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to demand for personalized medicine, rising in demand for humanized PDX models, growing incidence of cancer, focus on precision oncology, and increasing R&D investment for cancer research. Major trends in the forecast period include technological developments, rising demand for humanized PDX models, collaborative research initiatives, growing investments in cancer research, and increasing focus on immuno-oncology.

The demand for personalized medicine is expected to drive the growth of the patient-derived xenograft (PDX) models market. Personalized medicine tailors medical treatments to individual patient characteristics, such as genetics, environment, and lifestyle. This demand is rising due to advancements in genomic research, which facilitate treatments based on individual genetic profiles, leading to more effective and targeted healthcare. PDX models support personalized medicine by testing individual patient tumors to predict treatment responses and tailor therapies. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. Thus, the demand for personalized medicine fuels the growth of the PDX models market.

Major companies in the PDX models market are developing innovative models with in vivo bioluminescence imaging capabilities for real-time tumor growth monitoring. This imaging technique enhances PDX models by enabling non-invasive monitoring of tumor metastasis and treatment responses, improving the effectiveness of preclinical drug development research. For instance, in March 2024, InVitro Research Solutions Private Limited, an Indian Contract Research Organization (CRO), launched an innovative orthotopic model of human glioblastoma in NSG-SGM3 mice using PDX and in vivo bioluminescence imaging. This model aims to enable personalized treatment of glioblastoma, a highly aggressive brain cancer, and is critical for understanding glioblastoma biology and evaluating new targeted therapies and immunotherapies to improve outcomes.

In October 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Modifi Biosciences, Inc., for $1.3 billion. This acquisition aligns with Merck's strategy to enhance its oncology portfolio by incorporating Modifi's innovative research, which includes preclinical drug candidates and patient-derived xenograft model data, aimed at advancing therapies for cancers with DNA repair deficiencies. Modifi Biosciences, Inc. is a US-based biotechnology company focused on developing cancer therapeutics that target cancer cells through direct DNA modification.

Major companies operating in the patient derived xenograft (PDX) models market are Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., The Jackson Laboratory, Inotiv Inc, Biocytogen Pharmaceuticals Co. Ltd., Taconic Biosciences Inc, BioDuro-Sundia Inc, Horizon Discovery Ltd., Crown Bioscience Inc., Champions Oncology Inc., Oncodesign Services S.A, Genesis Biotechnology Group LLC., Creative Animodel, Abnova Corp., Certis Oncology Solutions Inc., Xentech, Aragen Bioscience Inc., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH., Urosphere, Hera BioLabs, InnoSer , Pharmatest Services Ltd., IVRS AB, Altogen Inc

North America was the largest region in the patient derived xenograft (PDX) models market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the patient derived xenograft (PDX) models market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The patient derived xenograft (PDX) models market includes revenues earned by entities by providing services such as evaluating drug efficacy, studying tumor biology, and predicting patient-specific treatment responses in preclinical cancer research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Patient Derived Xenograft (PDX) Models Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on patient derived xenograft (pdx) models market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for patient derived xenograft (pdx) models ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The patient derived xenograft (pdx) models market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Mice Models; Rat Models
• 2) By Technique: Heterotopic Implantation; Orthotropic Implantation
• 3) By Tumor Type: Gastrointestinal Tumor Models; Lung Tumor Models; Hematological Tumor Models; Gynecological Tumor Models; Respiratory Tumor Models; Urological Tumor Models; Other Tumor Models
• 4) By Application: Preclinical Drug Development; Precision Medicine; Co-Clinical Trials; Basic Cancer Research
• 5) By End-User: Academic And Research Organizations; Contract Research Organizations; Pharmaceutical And Biotechnological Companies; Other End-Users
• Subsegments:
• 1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice); Humanized Mice Models; Genetically Modified Mice Models
• 2) By Rat Models: Immunodeficient Rat Models; Humanized Rat Models; Genetically Modified Rat Models
• Companies Mentioned: Laboratory Corporation of America Holdings; WuXi AppTec Co. Ltd.; Charles River Laboratories International Inc.; The Jackson Laboratory; Inotiv Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Patient Derived Xenograft (PDX) Models Market Characteristics

3. Patient Derived Xenograft (PDX) Models Market Trends And Strategies

4. Patient Derived Xenograft (PDX) Models Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Patient Derived Xenograft (PDX) Models Growth Analysis And Strategic Analysis Framework

• 5.1. Global Patient Derived Xenograft (PDX) Models PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Patient Derived Xenograft (PDX) Models Market Growth Rate Analysis
• 5.4. Global Patient Derived Xenograft (PDX) Models Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Patient Derived Xenograft (PDX) Models Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Patient Derived Xenograft (PDX) Models Total Addressable Market (TAM)

6. Patient Derived Xenograft (PDX) Models Market Segmentation

• 6.1. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mice Models
• Rat Models
• 6.2. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heterotopic Implantation
• Orthotropic Implantation
• 6.3. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastrointestinal Tumor Models
• Lung Tumor Models
• Hematological Tumor Models
• Gynecological Tumor Models
• Respiratory Tumor Models
• Urological Tumor Models
• Other Tumor Models
• 6.4. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical Drug Development
• Precision Medicine
• Co-Clinical Trials
• Basic Cancer Research
• 6.5. Global Patient Derived Xenograft (PDX) Models Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Academic And Research Organizations
• Contract Research Organizations
• Pharmaceutical And Biotechnological Companies
• Other End-Users
• 6.6. Global Patient Derived Xenograft (PDX) Models Market, Sub-Segmentation Of Mice Models, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunodeficient Mice Models (Nude Mice, SCID Mice)
• Humanized Mice Models
• Genetically Modified Mice Models
• 6.7. Global Patient Derived Xenograft (PDX) Models Market, Sub-Segmentation Of Rat Models, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunodeficient Rat Models
• Humanized Rat Models
• Genetically Modified Rat Models

7. Patient Derived Xenograft (PDX) Models Market Regional And Country Analysis

• 7.1. Global Patient Derived Xenograft (PDX) Models Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Patient Derived Xenograft (PDX) Models Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Patient Derived Xenograft (PDX) Models Market

• 8.1. Asia-Pacific Patient Derived Xenograft (PDX) Models Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Patient Derived Xenograft (PDX) Models Market

• 9.1. China Patient Derived Xenograft (PDX) Models Market Overview
• 9.2. China Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Patient Derived Xenograft (PDX) Models Market

• 10.1. India Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Patient Derived Xenograft (PDX) Models Market

• 11.1. Japan Patient Derived Xenograft (PDX) Models Market Overview
• 11.2. Japan Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Patient Derived Xenograft (PDX) Models Market

• 12.1. Australia Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Patient Derived Xenograft (PDX) Models Market

• 13.1. Indonesia Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Patient Derived Xenograft (PDX) Models Market

• 14.1. South Korea Patient Derived Xenograft (PDX) Models Market Overview
• 14.2. South Korea Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Patient Derived Xenograft (PDX) Models Market

• 15.1. Western Europe Patient Derived Xenograft (PDX) Models Market Overview
• 15.2. Western Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Patient Derived Xenograft (PDX) Models Market

• 16.1. UK Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Patient Derived Xenograft (PDX) Models Market

• 17.1. Germany Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Patient Derived Xenograft (PDX) Models Market

• 18.1. France Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Patient Derived Xenograft (PDX) Models Market

• 19.1. Italy Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Patient Derived Xenograft (PDX) Models Market

• 20.1. Spain Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Patient Derived Xenograft (PDX) Models Market

• 21.1. Eastern Europe Patient Derived Xenograft (PDX) Models Market Overview
• 21.2. Eastern Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Patient Derived Xenograft (PDX) Models Market

• 22.1. Russia Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Patient Derived Xenograft (PDX) Models Market

• 23.1. North America Patient Derived Xenograft (PDX) Models Market Overview
• 23.2. North America Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Patient Derived Xenograft (PDX) Models Market

• 24.1. USA Patient Derived Xenograft (PDX) Models Market Overview
• 24.2. USA Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Patient Derived Xenograft (PDX) Models Market

• 25.1. Canada Patient Derived Xenograft (PDX) Models Market Overview
• 25.2. Canada Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Patient Derived Xenograft (PDX) Models Market

• 26.1. South America Patient Derived Xenograft (PDX) Models Market Overview
• 26.2. South America Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Patient Derived Xenograft (PDX) Models Market

• 27.1. Brazil Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Patient Derived Xenograft (PDX) Models Market

• 28.1. Middle East Patient Derived Xenograft (PDX) Models Market Overview
• 28.2. Middle East Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Patient Derived Xenograft (PDX) Models Market

• 29.1. Africa Patient Derived Xenograft (PDX) Models Market Overview
• 29.2. Africa Patient Derived Xenograft (PDX) Models Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Patient Derived Xenograft (PDX) Models Market, Segmentation By Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Patient Derived Xenograft (PDX) Models Market, Segmentation By Tumor Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Patient Derived Xenograft (PDX) Models Market Competitive Landscape And Company Profiles

• 30.1. Patient Derived Xenograft (PDX) Models Market Competitive Landscape
• 30.2. Patient Derived Xenograft (PDX) Models Market Company Profiles
  • 30.2.1. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Charles River Laboratories International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. The Jackson Laboratory Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Inotiv Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Patient Derived Xenograft (PDX) Models Market Other Major And Innovative Companies

• 31.1. Biocytogen Pharmaceuticals Co. Ltd.
• 31.2. Taconic Biosciences Inc.
• 31.3. BioDuro-Sundia Inc.
• 31.4. Horizon Discovery Ltd.
• 31.5. Crown Bioscience Inc.
• 31.6. Champions Oncology Inc.
• 31.7. Oncodesign Services S.A.
• 31.8. Genesis Biotechnology Group LLC.
• 31.9. Creative Animodel
• 31.10. Abnova Corp.
• 31.11. Certis Oncology Solutions Inc.
• 31.12. Xentech
• 31.13. Aragen Bioscience Inc.
• 31.14. EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH.
• 31.15. Urosphere

32. Global Patient Derived Xenograft (PDX) Models Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Patient Derived Xenograft (PDX) Models Market

34. Recent Developments In The Patient Derived Xenograft (PDX) Models Market

35. Patient Derived Xenograft (PDX) Models Market High Potential Countries, Segments and Strategies

• 35.1 Patient Derived Xenograft (PDX) Models Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Patient Derived Xenograft (PDX) Models Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Patient Derived Xenograft (PDX) Models Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer